{"id":63442,"date":"2026-04-17T21:25:24","date_gmt":"2026-04-17T13:25:24","guid":{"rendered":"https:\/\/flcube.com\/?p=63442"},"modified":"2026-04-17T21:25:25","modified_gmt":"2026-04-17T13:25:25","slug":"abbott-reports-3-8-yoy-revenue-growth-in-q1-2026-led-by-diagnostics-and-medical-devices","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63442","title":{"rendered":"Abbott Reports 3.8% YOY Revenue Growth in Q1 2026, Led by Diagnostics and Medical Devices"},"content":{"rendered":"\n

Abbott Laboratories<\/strong> (NYSE: ABT<\/a>) announced its financial results for the first quarter of 2026, reporting revenue of USD 11.164 billion<\/strong>, a 3.8% increase year-over-year (YOY)<\/strong>. Growth was broad-based across its key segments, with the Diagnostics, Established Pharmaceuticals, and Medical Devices<\/strong> businesses all posting gains, while the Nutrition<\/strong> segment declined.<\/p>\n\n\n\n

Segment Performance Breakdown<\/h2>\n\n\n\n
Segment<\/th>Key Highlights<\/th><\/tr><\/thead>
Diagnostics<\/strong><\/td>\u2022 Cancer diagnostics<\/strong> surged, fueled by Exact Sciences<\/strong> contribution.
\u2022 Cologuard<\/strong> achieved double-digit growth; new Cancerguard<\/strong> multi-cancer test showed strong initial performance.
\u2022 Core Laboratory<\/strong> business grew YOY and sequentially, driven by the U.S., Europe, and Latin America.
\u2022 Rapid & Molecular Diagnostics<\/strong> saw lower demand YOY due to a milder respiratory virus season.<\/td><\/tr>
Medical Devices<\/strong><\/td>\u2022 Electrophysiology, Heart Failure, and Rhythm Management<\/strong> businesses all delivered double-digit growth<\/strong>.
\u2022 Diabetes Care<\/strong>, powered by its continuous glucose monitoring (CGM)<\/strong> portfolio, grew 7.6%<\/strong>.<\/td><\/tr>
Established Pharmaceuticals<\/strong><\/td>\u2022 Key emerging markets<\/strong> (Latin America, Asia-Pacific, etc.) posted stellar 12.9% reported sales growth<\/strong>, driven by its branded generics portfolio.<\/td><\/tr>
Nutrition<\/strong><\/td>\u2022 Global sales declined due to lower volumes<\/strong> and the impact of pricing actions<\/strong> implemented in Q4 2025.
\u2022 The company anticipates volume improvement<\/strong> throughout 2026, supported by new product launches.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Outlook<\/h2>\n\n\n\n

Abbott\u2019s Q1 results demonstrate the resilience and diversification of its healthcare portfolio. The strong performance in high-growth areas like cancer diagnostics, cardiac rhythm management, and emerging market pharmaceuticals more than offset the temporary softness in its Nutrition business. The successful integration of Exact Sciences continues to be a major value driver, while its CGM platform remains a key growth engine in the competitive diabetes market.<\/p>\n\n\n\n

Management expressed confidence in its full-year outlook, citing a robust pipeline and the expected recovery in its Nutrition segment as new products gain traction.<\/p>\n\n\n\n

Forward-Looking Statements<\/strong>
This brief contains forward-looking statements regarding Abbott\u2019s future financial performance and business strategy. Actual results may differ materially due to factors including market competition, regulatory changes, and global economic conditions.-Fineline Info & Tech<\/a><\/p>\n\n\n\n